Navigation Links
AMRI Awarded Development and Manufacture Contract from the UK Government
Date:9/30/2013

ALBANY, N.Y., Sept. 30, 2013 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced that its wholly owned subsidiary, Albany Molecular Research (UK) Ltd., located in Holywell, Wales, United Kingdom, has been awarded a seven-year contract  for the development and manufacture of an active ingredient under clinical evaluation. The contract was awarded by the Defense Science and Technology Laboratory (Dstl), acting on behalf of the United Kingdom's Secretary of State for Defence, the Department of National Defence of Canada and Minister of Defence of the Kingdom of the Netherlands.

AMRI will initially work on the development and scale-up of the investigational drug, and subsequently the manufacture and supply for use during phase 1 clinical trials. If the trials are successful, AMRI will be in a strong position to become the commercial manufacturer of the product for distribution to the government partners of this contract including the United Kingdom, Netherlands and Canada.

"We are excited for the opportunity to work on this important project for the UK government," said AMRI's President and CEO, Thomas E. D'Ambra, Ph.D. "Government contracts and related collaborations outside of our typical outsourcing contracts with biotechnology and pharmaceutical companies are part of our strategy to diversify our revenue base while making our high-quality services available to all industries, sectors and organizations that can benefit from our strengths in discovery, development and manufacturing."

This collaboration underscores AMRI's expertise in providing SMARTSOURCING™ solutions to government agencies working to solve critical health issues. This includes work as both a contractor and subcontractor for various agencies of the U.S. government. AMRI has been a subcontractor in the manufacturing arena for the U.S. Department of Defense for more than a decade. In August 2011, AMRI received a federal contract award from the National Institutes of Health (NIH) / National Institute of Neurological Disorders and Stroke (NINDS) to provide chemistry and other drug discovery technologies in support of NINDS' Medicinal Chemistry for Neurotherapeutics Program (MCNP), part of the NIH Blueprint Neurotherapeutics Network (BPN). This five-year contract provides AMRI with funding of up to $43 million, based on the number of approved projects and availability of funds.

About AMRI
Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development and manufacturing services. For over 21 years, AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCING, a full range of value-added opportunities providing customers with informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline. AMRI has also successfully partnered R&D programs and is actively seeking to out-license its remaining programs for further development. For more information about AMRI, please visit our website at http://www.amriglobal.com/ or follow us on Twitter (@amriglobal).

About Albany Molecular Research (UK) Ltd.
Albany Molecular Research (UK) Ltd., a wholly owned subsidiary of AMRI, provides development and manufacturing services, including pre-clinical and Phase I – III product development, as well as commercial manufacturing for approved products. The 14-acre site is located about 60 miles outside of Manchester, England and contains Kilo lab, pilot plant and large-scale manufacturing capabilities. In 2012, the site received a Good Manufacturing Practice (GMP) certificate from the Medicines and Healthcare Regulatory Agency (MHRA) of the UK government for AMRI's manufacturing facility in Holywell, Wales, UK, underscoring the quality of the facility and its growth potential.


'/>"/>
SOURCE AMRI
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Numotion Awarded Best Complex Rehab Provider
2. Isis Pharmaceuticals Stanley Crooke Awarded Corporate Forums Director of the Year
3. Access Pharmaceuticals Awarded Second European Patent for MuGard
4. Jeannette R. Jakus, MD, MBA, Awarded American Academy of Dermatology Translational Biotechnology Fellowship
5. Oligomerix Awarded Phase IIB Grant From the NIH to Discover Drugs that Inhibit Alzheimers Disease Progression
6. NovelMed Awarded NIH Fast Track SBIR Grant for $1.43 Million to Advance Development of its Anti-Complement Antibody for Orphan Disease
7. Carolina Piedmont Capital Awarded VOSB Certification
8. B. Braun Awarded Premier Healthcare Alliance Contract for Dual-Source IV
9. Novan Awarded $7.8 Million Contract by BARDA to Develop a Medical Countermeasure for Thermal Burns
10. Fountain Valley Regional Medical Center Becomes Orange Countys First Hospital Awarded Advanced Certification In Inpatient Diabetes Care
11. aTyr Pharma Awarded Two Patents from USPTO to Support Development of New Therapeutics Based on Physiocrine Biology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), will ... and webcast on Friday, November 3, 2017, beginning at ... at approximately 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... financial performance and guidance for 2018, Hill-Rom executives will ... operational performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
(Date:9/22/2017)... -- AVACEN Medical (AVACEN) announced that its CE-Marked AVACEN ... with the widespread pain associated with fibromyalgia in the ... Essex, England commented, "I had difficulty ... sleep at all, tremendous pain, with every movement sending ... AVACEN 100] enough, how this has and is helping ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... 2017 , ... The American College of Medical Informatics (ACMI) will present the ... Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium ... a pioneer in the field of medical informatics, this prestigious award is presented to ...
(Date:10/12/2017)... Maryland (PRWEB) , ... October 12, 2017 , ... ... magnetic drug delivery system that we intend to develop to enable prevention of ... can lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader ... a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were ... 11, 2017. , The annual award competition recognizes editorial and design excellence across a ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the ... – Miles by Moonlight to raise money for the American Heart Association Heart Walk. ... , Teams will work together to keep their treadmills moving for 5 hours. Treadmills ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy ... health literacy software tool, and the Cancer Patient Education Network (CPEN), an independent ... today announce a new strategic alliance. , As CPEN’s strategic partner, HLI ...
Breaking Medicine News(10 mins):